Welcome to our dedicated page for iRhythm Holdings SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iRhythm Technologies, Inc. (NASDAQ: IRTC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public issuer. As a digital health care company focused on ambulatory cardiac monitoring and data analytics, iRhythm uses its SEC reports to communicate financial performance, risk factors, governance matters, and material corporate events related to its Zio long-term continuous monitoring (LTCM) service and broader operations.
Investors can use this page to review current and historical filings retrieved from the SEC’s EDGAR system, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. Recent 8-K filings have covered topics such as quarterly financial results, investor presentations, and amendments to the Executive Change in Control and Severance Policy, which outlines severance payments, COBRA coverage, and equity vesting treatment for senior leaders under specified termination scenarios.
For those analyzing iRhythm’s business in more depth, the company’s periodic reports typically discuss revenue from Zio services, gross margins, operating expenses, non-GAAP measures like adjusted EBITDA and adjusted net loss, and liquidity metrics such as cash, cash equivalents, and marketable securities. These documents also describe how iRhythm accounts for items like stock-based compensation, business transformation costs, and other adjustments that affect non-GAAP results.
Stock Titan enhances access to these filings with AI-powered summaries that help explain the key points of lengthy documents, such as 10-K and 10-Q reports, in more accessible language. Users can quickly identify major changes in financial condition, updates to risk disclosures, and details of insider or executive-related arrangements that appear in forms and exhibits. This combination of real-time filing access and AI-generated insights can support investors, analysts, and other stakeholders who want to understand how iRhythm reports on its digital cardiac monitoring business and corporate governance over time.
The Vanguard Group filed Amendment No. 7 to a Schedule 13G/A reporting 0 shares of iRhythm Holdings Inc. common stock as of 03/13/2026. The filing explains an internal realignment on January 12, 2026 that caused certain Vanguard subsidiaries and business divisions to report beneficial ownership separately. The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
iRhythm Holdings filed a Schedule 13G reporting that Millennium Management LLC and related filers beneficially own 1,664,203 shares of Common Stock, representing 5.1% of the class. The filing states these shares are held by entities over which Millennium and related managers have shared voting and dispositive power.
The filing is a joint filing by Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander and includes a Joint Filing Agreement dated March 20, 2026.
Patten Jason H reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings director Jason H. Patten received a grant of 2,218 restricted stock units (RSUs) of Common Stock. Each RSU represents a contingent right to one share of iRhythm’s common stock. The RSUs vest 33.33% on March 12, 2027 and on each one-year anniversary thereafter, as long as he continues as a service provider. Following this award, Patten directly holds 4,436 shares/RSUs reported in this filing.
iRhythm Holdings, Inc. director Jason H. Patten has filed an initial ownership report on Form 3. This filing establishes his status as a director and provides a baseline disclosure of his holdings in the company, with no buy, sell, or other insider transactions reported in this statement.
iRhythm Holdings EVP Mervin Smith reported an open-market sale of 2,585 shares of common stock at $114.30 per share. The transaction took place on March 16, 2026 and was executed under a pre-established Rule 10b5-1 trading plan adopted on November 19, 2025.
After this sale, Smith continues to hold 23,027 shares directly, indicating he retains a substantial equity position in the company despite the disposition.
Mervin Smith reported proposed sales of Common Stock tied to performance shares. The filing lists 2,585 performance shares with a transaction date of 02/24/2026 and identifies the broker Morgan Stanley Smith Barney LLC.
The filing also records prior sales by Mervin Smith during the past three months: 1,352 shares on 03/02/2026 for $173,652.33, 4,041 shares on 02/25/2026 for $547,227.77, and 732 shares on 02/24/2026 for $103,146.12.
iRhythm Holdings, Inc. appointed Jason Patten to its Board of Directors and Audit Committee, effective March 12, 2026, with a term running until the 2026 annual stockholder meeting. The Board determined he qualifies as an independent director and meets SEC Rule 10A-3 audit committee standards and Nasdaq listing requirements.
Under the non-employee Director Compensation Policy, Patten received an initial restricted stock unit grant with a grant date value of $300,000, vesting annually over three years following March 12, 2026, and accelerating upon a change of control if he remains in service. He will also receive an annual cash retainer of $55,000 for Board service and $10,000 for Audit Committee service, paid quarterly. Before joining the Board, he advised the CEO and was paid $86,771 in cash for that role.
iRhythm Holdings, Inc. reported that executive officer Minang Turakhia, its chief medical and scientific officer, executed open-market sales of a total of 4,027 shares of common stock on March 2, 2026 at prices around $128.45 per share. According to the footnote, these shares were sold specifically to cover tax withholding and remittance obligations arising from the vesting of restricted stock units. Following these transactions, Turakhia directly holds 54,906 shares of iRhythm common stock.
iRhythm Holdings, Inc. executive Sumi Shrishrimal, EVP and Chief Risk Officer, reported selling a total of 2,830 shares of common stock in three open-market transactions on March 2, 2026 at prices around $128.44 per share. According to the disclosure, these shares were sold to cover tax withholding and remittance obligations related to the vesting of Restricted Stock Units (RSUs). Following these sales, Shrishrimal directly owned 41,870 shares of iRhythm common stock.
iRhythm Holdings, Inc. executive vice president of strategic business operations Mervin Smith reported selling 1,352 shares of common stock on March 2, 2026 in open‑market transactions at prices around $128.44 per share. The filing states the shares were sold to cover tax withholding obligations from vesting restricted stock units, and Smith held 25,612 shares afterward.